Journal of Addiction Medicine
November 16, 2021
Christian Hailozian, Joshua Luftig, Amy Liang et al.
Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine's high-affinity blockade at mu-opioid receptors (μORs). Buprenorphine's partial agonism (low intrinsic efficacy) at μORs can limit the effectiveness of even massive doses once BPOW has begun. Adjunct medications, such as clonidine, are rarely effective...
Scholarly Research In Progress
November 8, 2021
Sankung X. Darboe, Peter J. Koszuta, Paul W. Lee et al.
The anesthetic agent ketamine has been under investigation as a potential antidepressant for two decades. Animal studies and subsequent randomized control trials for patients have provided extensive evidence of ketamine’s rapid antidepressant outcomes both structurally at the receptor level as well as behaviorally. A review of current literature hones in on the putative rapid mechanisms of...
Life
November 5, 2021
Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski et al.
16 citations
The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the...
The Brown University Psychopharmacology Update
November 1, 2021
Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found. The results suggest that a full 4‐week induction of esketamine with an oral antidepressant may optimize treatment outcomes, the researchers...
Consciousness and Cognition
November 1, 2021
Linda Radek, Lauri Koskinen, Nils Sandman et al.
To understand how anesthetics with different molecular mechanisms affect consciousness, we explored subjective experiences recalled after responsive and unresponsive sedation induced with equisedative doses of dexmedetomidine, propofol, sevoflurane, and S-ketamine in healthy male participants (N = 140). The anesthetics were administered in experimental setting using target-controlled infusion...
Brain, Behavior, & Immunity - Health
November 1, 2021
N. Nikkheslat
67 citations
Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial aetiology and complex pathophysiology. Despite availability of various pharmacological and non-pharmacological therapeutic strategies, treatment resistant depression (TRD) remains a significant challenge with specific concern for those patients with severe depressive symptoms in particular suicidal ideations...
Journal of Psychiatric Practice
November 1, 2021
Amir Garakani
Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form. The 3 cases presented in this issue deal with an array of clinical considerations in treating patients with TRD, including the use of ECT in...
BMC Psychiatry
October 31, 2021
Nagahide Takahashi, Aya Yamada, Ayako Shiraishi et al.
56 citations
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TRD needs to be assessed. Methods This Phase 2b, randomized, double-blind (DB), placebo-controlled...
Frontiers in Pharmacology
October 27, 2021
Nafsika Poulia, Foteini Delis, Charalampos Brakatselos et al.
Clinical evidence and experimental studies have shown the psychotomimetic properties induced by ketamine. Moreover, acute or chronic ketamine (KET) administration has been widely used for modeling schizophrenia-like symptomatology and pathophysiology. Several studies have reported the antipsychotic potential of cannabidiol (CBD), while there is limited information on the cannabidiol effect on...
European Journal of Clinical Pharmacology
October 27, 2021
T. Lima, M. B. Visacri, P. M. Aguiar
38 citations
To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled trials on the use of ketamine and esketamine in adult patients with depression. Two authors independently...
Frontiers in Psychiatry
October 18, 2021
Alina Wilkowska, Mariusz S. Wiglusz, Maria Gałuszko‐węgielnik et al.
35 citations
Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel, rapid acting strategy for treatment resistant depression. Here we report the change in symptoms of anhedonia measured by Snaith-Hamilton Pleasure...
Open Access Indonesian Journal of Medical Reviews
October 15, 2021
Lovina Lovina
Depressive disorder is still a significant problem in several developed countriesand is morbidity caused by mental disorders. With the development of science,now discovered the unique pharmacodynamic properties of ketamine, which isused as an antidepressant. As we know in clinical practice, ketamine is used foranaesthesia, analgesia, sedation, and chronic pain management....
Cochrane Database of Systematic Reviews
October 8, 2021
Rebecca L. Dean, Tahnee Marquardt, Claudia C. Hurducas et al.
41 citations
BACKGROUND Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar...
Brain Research Bulletin
October 1, 2021
I. Ishola, Benneth Ben-Azu, Oluwatosin A. Adebayo et al.
Currently, prevailing evidence have identified cholinergic and oxidative pathways as important therapeutic targets for abating ketamine-induced schizophrenia-like behavior. Thus, this study evaluated the ability of hesperidin, a naturally occurring antioxidant and neuroprotective flavonoid, to prevent and reverse ketamine-induced schizophrenia-like behaviors and changes in cholinergic,...
Revista de Psiquiatría y Salud Mental
October 1, 2021
M. N. Fullana, Verónica Paz, Francesc Artigas et al.
OBJECTIVE Recently, we reported on a new MDD-like mouse model based on a regionally selective knockdown of astroglial glutamate transporters, GLAST/GLT-1, in infralimbic cortex (IL) which evokes widespread changes in mouse brain associated with the typical alterations found in MDD patients. To further characterize this new MDD-like mouse model, here we examine some transcriptional elements of...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
October 1, 2021
N. Kraguljac, Matthew S. Carle, M. Frölich et al.
Background: Converging evidence from neuroimaging and post-mortem studies suggests that hippocampal subfields are differentially affected in schizophrenia. Recent studies report dentate gyrus dysfunction in chronic schizophrenia, but the underlying mechanisms remain to be elucidated. Here we sought examine if this deficit is already present in first episode psychosis, and if...
Clinical Neurophysiology
October 1, 2021
Shubham Chamadia, Jacob Gitlin, Jennifer Mekonnen et al.
Objective: Ketamine is an anesthetic drug associated with dissociation. Decreased electroencephalogram alpha (8 to 13 Hz) and low-beta (13 to 20 Hz) oscillation power have been associated with ketamine-induced dissociation. We aimed to characterize surface electroencephalogram signatures that may serve as biomarkers for dissociation. Methods: We analyzed data from a single-site, open-label,...
International Psychogeriatrics
October 1, 2021
J. Leal, Maria I Lapid, Simon Kung
Treatment resistant depression can be very disabling and has a significant negative impact on a patient, their family or caregivers, and the society. There is a growing evidence on the efficacy and safety of ketamine for treatment resistant depression. Ketamine is a racemate consisting of esketamine and arketamine, is an N-methyl D-aspartate receptor antagonist and comes in different...
Journal of Child and Adolescent Psychopharmacology
October 1, 2021
David S. Mathai, Alexis G. McCathern, Andrew G. Guzick et al.
14 citations
Objectives: Investigation into parental decision-making processes involving ketamine is of high priority, given the necessary role of parents in consenting to treatment. In this study, we examined parental attitudes toward the emerging use of ketamine in adolescent mood disorders and suicidality. Methods: Two hundred eighty-three English-speaking parents completed an online survey using Amazon...
Journal of Psychedelic Studies
October 1, 2021
Alan K. Davis, Pratheek Mangini, Yitong Xin
10 citations
Abstract Trauma exposure across the lifespan produces risks for posttraumatic stress disorder (PTSD), depression, anxiety, as well as global disability in functioning. This retrospective clinical chart review is the first of its kind to assess the utility of sublingual ketamine-assisted body-centered psychotherapy in trauma-exposed patients in a real world clinic setting. De-identified clinical...